UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported 05/30/2008)
Med Gen Inc.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 000-29171 65-0703559
--------------------------- ---------------- ------------------
(State or other Jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
7280 West Palmetto Park Road, Suite #306, Boca Raton, FL 33433
--------------------------------------------------------------
(Address of principal executive offices)
561-750-1100
--------------------------
(Issuer's telephone number)
Not Applicable
------------------------------------------------------------
(Former name or former address, if changed since last report)
All Correspondence to:
Paul B Kravitz CEO
c/o Med Gen Inc.
7280 West Palmetto Park Road
Suite #306
Boca Raton, Florida 33433
Item 8.01 Other Events.
The Company has been approved by the NASDAQ for a 1:200 reverse split, effective June 2nd, 2008.
The new symbol will beMDIN.
All fractional shares will be rounded down.
The Company has 4,709,806,676common shares outstanding as of the date of this filing and over 1800 total shareholders per ADP non-objecting beneficial owners list. The Company is authorized to issue up to 12,495,000,000 total common shares.
The Company will have 23,549,033 common shares outstanding after the reverse and approximately 1200 total shareholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Med Gen Inc.
Date: May 30th, 2008
/s/Paul B. Kravitz
----------------------------------
Paul B. Kravitz,
Chairman & Chief Executive Officer
